The estimated Net Worth of Roberto Mignone is at least $26.8 Milhão dollars as of 18 June 2024. Mr. Mignone owns over 519,000 units of Teva- Pharmaceutical Industries stock worth over $17,618,760 and over the last 6 years he sold TEVA stock worth over $8,838,570. In addition, he makes $339,999 as Independent Director at Teva- Pharmaceutical Industries.
Roberto has made over 9 trades of the Teva- Pharmaceutical Industries stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 519,000 units of TEVA stock worth $8,838,570 on 18 June 2024.
The largest trade he's ever made was buying 750,000 units of Teva- Pharmaceutical Industries stock on 9 May 2018 worth over $14,430,000. On average, Roberto trades about 85,293 units every 140 days since 2018. As of 18 June 2024 he still owns at least 981,000 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Mr. Mignone stock trades at the bottom of the page.
Roberto A. Mignone serves as Independent Director of the Company. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, a multi-billion dollar investment management firm founded in 2000 and specializing in long-term equity strategies. Since inception, Bridger Management has focused on the healthcare sector and has developed considerable research expertise in support of its investments. In addition to healthcare, Bridger Management invests in global consumer, technology and financial services companies. Prior to Bridger Management, Mr. Mignone co-founded and served as a partner of Blue Ridge Capital LLC from 1996 to 2000, an investment management firm specialized in health care, technology, media, telecommunications and financial services. Mr. Mignone serves as a trustee and member of the Finance Committee and Nominating Committee of the New York University Langone Medical Center.
As the Independent Director of Teva- Pharmaceutical Industries, the total compensation of Roberto Mignone at Teva- Pharmaceutical Industries is $339,999. There are 14 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
Roberto Mignone is 48, he's been the Independent Director of Teva- Pharmaceutical Industries since 2017. There are 25 older and 3 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
Roberto's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks, eRoberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include: